Thrivent Financial for Lutherans Raises Stock Position in Abbott Laboratories $ABT

Thrivent Financial for Lutherans boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 24.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 246,586 shares of the healthcare product maker’s stock after purchasing an additional 48,286 shares during the period. Thrivent Financial for Lutherans’ holdings in Abbott Laboratories were worth $30,931,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Maxele Advisors LLC grew its holdings in shares of Abbott Laboratories by 6.5% during the fourth quarter. Maxele Advisors LLC now owns 11,406 shares of the healthcare product maker’s stock worth $1,429,000 after purchasing an additional 700 shares in the last quarter. Williams & Novak LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $667,000. Arbejdsmarkedets Tillaegspension purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $24,034,000. Conning Inc. grew its holdings in shares of Abbott Laboratories by 8.4% during the fourth quarter. Conning Inc. now owns 274,468 shares of the healthcare product maker’s stock worth $34,388,000 after purchasing an additional 21,178 shares in the last quarter. Finally, New York Life Investment Management LLC grew its holdings in shares of Abbott Laboratories by 0.9% during the fourth quarter. New York Life Investment Management LLC now owns 238,369 shares of the healthcare product maker’s stock worth $29,865,000 after purchasing an additional 2,055 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ABT. TD Cowen cut their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. BTIG Research reissued a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a report on Monday, April 27th. Citigroup dropped their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Mizuho dropped their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Argus dropped their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.43.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $84.49 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The stock has a 50 day moving average price of $99.02 and a two-hundred day moving average price of $113.25. The company has a market capitalization of $147.16 billion, a P/E ratio of 23.67, a PEG ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the company posted $1.09 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 3.0%. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.